New Third Rock company emerges from stealth with $121 million financing

Cambridge, USA-based Merida Bioscienes, a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate the pathogenic antibody drivers of multiple serious autoimmune and allergic diseases, has announced its launch alongside a $121million financing.

There is a central problem facing autoimmune disease therapies today, the company noted, saying today’s standard of care wields a sledgehammer rather than a scalpel against the immune system, leaving patients immunocompromised and burdened with side effects that often amount to the equivalent of an illness themselves.

The financing was co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, joined by GV and Perceptive Xontogeny Venture Funds (PXV Funds). Merida was seeded in 2022 by Third Rock Ventures.